Related Experiment Video
Updated: May 2, 2026
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
5.3K
We really need to talk: adapting FDA processes to rapid change
1Harvard Law School, USA.
Food and Drug Law Journal
|February 21, 2014
Summary
Modern commerce challenges traditional Food and Drug Administration (FDA) regulations. This analysis suggests improving FDA warning letters by examining other agencies
Area of Science:
- Regulatory Science
- Public Health Policy
- Market Surveillance
Background:
- Traditional regulatory frameworks struggle with rapid advancements in modern commerce.
- The Food and Drug Administration's (FDA) crisis-response regulations have evolved historically.
- New market entrants and products challenge existing definitions and procedures.
Observation:
- Discrepancies arise between actual product/marketing controls and consumer expectations.
- Some market actions are not in good faith, exacerbating regulatory challenges.
- Rapid innovation environments strain established regulatory paradigms.
Findings:
- Analysis of FDA's historical crisis-response regulation reveals limitations.
- Other federal agencies employ techniques to manage rapid innovation.
- Current FDA warning letter system may require enhancements.
Implications:
- Recommendations for improving the FDA's warning letter system are proposed.
- Adapting regulatory approaches is crucial for overseeing novel products.
- Ensuring alignment between product reality and consumer perception is vital.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
343
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
343
01:25Drug Regulation
3.0K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:11Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
547
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
547
01:13Bioequivalence studies: Biowaivers
430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430